Results 31 to 40 of about 2,283,209 (217)

Summary of radioligand receptor binding assay components and reactions according to each receptor.

open access: yes, 2015
Summary of radioligand receptor binding assay components and reactions according to each receptor.
Sek Peng Chin (737715)   +5 more
core   +1 more source

DESIGN AND SYNTHESIS OF A PIPERAZINE DERIVATIVE AS A HIGH AFFINITY 5-HTIA RECEPTOR LIGAND

open access: yesZagazig Journal of Pharmaceutical Sciences, 1993
Serotonin (5-HT) 1A receptors have been shown to have physiological, biochemical pharmacological and clinical values. The piperazino derivative 1 was rationally designed as a bulky, lipophilic N4-substituted arylpiperazine. Radioligand binding assay of 1
Mohamed El-Bermawy
doaj   +1 more source

Pharmacological Characterization of Purified Full-Length Dopamine Transporter from Drosophila melanogaster

open access: yesCells, 2022
The dopamine transporter (DAT) is a member of the neurotransmitter:sodium symporter (NSS) family, mediating the sodium-driven reuptake of dopamine from the extracellular space thereby terminating dopaminergic neurotransmission.
Ciara Frances Pugh   +3 more
doaj   +1 more source

Identification of Optically Active Pyrimidine Derivatives as Selective 5-HT2C Modulators

open access: yesMolecules, 2017
A series of pyrimidine derivatives 4a–i were synthesized and evaluated for their binding affinities towards 5-HT2C receptors. With regard to designed molecules 4a–i, the influence of the size of alkyl ether and the absolute configuration of a stereogenic
Juhyeon Kim   +7 more
doaj   +1 more source

Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer

open access: yesMolecules, 2021
Bladder cancer (BC) is the tenth most frequently detected cancer in both sexes. Type-I luteinizing hormone-releasing hormone (LHRH) receptor (LHRH-R-I) is expressed not only in the pituitary, but also in several types of cancer disease.
Zsuzsanna Szabó   +11 more
doaj   +1 more source

Radioligand binding methods: practical guide and tips

open access: yes, 1993
Radioligand binding assays are a relatively simple but extremely powerful tool for studying receptors. They allow an analysis of the interactions of hormones, neurotransmitters, growth factors, and related drugs with the receptors, studies of receptor ...
D. B. Bylund, M. L. Toews
core   +1 more source

Analyzing Radioligand Binding Data [PDF]

open access: yes, 2000
A radioligand is a radioactively labeled drug that can associate with a receptor, transporter, enzyme, or any protein of interest. Measuring the rate and extent of binding provides information on the number of binding sites, and their affinity and ...
Neubig, Richard   +3 more
core   +1 more source

Assay of CB1 Receptor Binding.

open access: yes, 2016
Type-1 cannabinoid receptor (CB1), one of the main targets of endocannabinoids, plays a key role in several pathophysiological conditions that affect both central nervous system and peripheral tissues.
CATANI, MV   +6 more
core   +2 more sources

FRET-based Microscopy Assay to Measure Activity of Membrane Amino Acid Transporters with Single-transporter Resolution

open access: yesBio-Protocol, 2021
Secondary active transporters reside in cell membranes transporting polar solutes like amino acids against steep concentration gradients, using electrochemical gradients of ions as energy sources.
Didar Ciftci   +8 more
doaj   +1 more source

Stage‐Specific Patterns of Imaging and Non‐Motor Biomarkers in Spinocerebellar Ataxia Type 3

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Advancements in disease‐modifying therapies for spinocerebellar ataxia Type 3 (SCA3) underscore the need for robust biomarkers to monitor disease progression and evaluate treatment efficacy. Although motor phenotypes have been well characterized, less is known about non‐motor and imaging‐based features across different disease stages.
Chun Li   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy